145 related articles for article (PubMed ID: 17694505)
1. Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.
Ceriello A; Lush CW; Darsow T; Piconi L; Corgnali M; Nanayakkara N; Frias JP; Maggs D
Diabetes Metab Res Rev; 2008 Feb; 24(2):103-8. PubMed ID: 17694505
[TBL] [Abstract][Full Text] [Related]
2. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
3. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.
Ceriello A; Piconi L; Quagliaro L; Wang Y; Schnabel CA; Ruggles JA; Gloster MA; Maggs DG; Weyer C
Diabetes Care; 2005 Mar; 28(3):632-7. PubMed ID: 15735200
[TBL] [Abstract][Full Text] [Related]
4. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
[TBL] [Abstract][Full Text] [Related]
5. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.
Thompson RG; Gottlieb A; Organ K; Koda J; Kisicki J; Kolterman OG
Diabet Med; 1997 Jul; 14(7):547-55. PubMed ID: 9223392
[TBL] [Abstract][Full Text] [Related]
6. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
Chase HP; Lutz K; Pencek R; Zhang B; Porter L
J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
[TBL] [Abstract][Full Text] [Related]
7. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
[TBL] [Abstract][Full Text] [Related]
8. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
Singh-Franco D; Robles G; Gazze D
Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
[TBL] [Abstract][Full Text] [Related]
9. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
[TBL] [Abstract][Full Text] [Related]
10. Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls.
Neri S; Signorelli SS; Torrisi B; Pulvirenti D; Mauceri B; Abate G; Ignaccolo L; Bordonaro F; Cilio D; Calvagno S; Leotta C
Clin Ther; 2005 Nov; 27(11):1764-73. PubMed ID: 16368447
[TBL] [Abstract][Full Text] [Related]
11. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
Ryan GJ; Jobe LJ; Martin R
Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
[TBL] [Abstract][Full Text] [Related]
12. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
[TBL] [Abstract][Full Text] [Related]
13. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
14. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
15. Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs.
Peyrot M; Rubin RR; Polonsky WH; Best JH
Curr Med Res Opin; 2010 May; 26(5):1047-54. PubMed ID: 20199136
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
Edelman S; Garg S; Frias J; Maggs D; Wang Y; Zhang B; Strobel S; Lutz K; Kolterman O
Diabetes Care; 2006 Oct; 29(10):2189-95. PubMed ID: 17003291
[TBL] [Abstract][Full Text] [Related]
17. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.
Riddle M; Pencek R; Charenkavanich S; Lutz K; Wilhelm K; Porter L
Diabetes Care; 2009 Sep; 32(9):1577-82. PubMed ID: 19502544
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial comparing the effect of basal insulin and inhaled mealtime insulin on glucose variability and oxidative stress.
Siegelaar SE; Kulik W; van Lenthe H; Mukherjee R; Hoekstra JB; Devries JH
Diabetes Obes Metab; 2009 Jul; 11(7):709-14. PubMed ID: 19320663
[TBL] [Abstract][Full Text] [Related]
20. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
